Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$1.37 USD
+0.08 (6.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.40 +0.03 (2.19%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HEPA 1.37 +0.08(6.20%)
Will HEPA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HEPA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HEPA
Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Bet
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
HEPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?
Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?
Other News for HEPA
Biotech Alert: Searches spiking for these stocks today
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
12 Health Care Stocks Moving In Monday's Intraday Session
Gold Falls Sharply; Matterport Shares Spike Higher
Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts